Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Gonadal Disorders

ClinicalTrials.gov lists 5,914 trials for Gonadal Disorders or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 202.

MeSH D006058 Endocrine System Diseases C19
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 973 Phase 1/2 Phase 1/2 420 Phase 2 Phase 2 1,166 Phase 2/3 Phase 2/3 63 Phase 3 Phase 3 483 Phase 4 Phase 4 291 Not applicable Not applicable 1,183 Observational Observational 1,326 Phase 1 Phase 1 973 Phase 1/2 Phase 1/2 420 Phase 2 Phase 2 1,166 Phase 2/3 Phase 2/3 63 Phase 3 Phase 3 483 Phase 4 Phase 4 291 Not applicable Not applicable 1,183 Observational Observational 1,326

Trials per phase (log scale)

1 more section with rows

25 of the 5,914 trials are tagged with Gonadal Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Gonadal Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Gonadal Disorders trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 12 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 345

1990: 5 trials (Observational 1, Not applicable 2, Phase 2 1, Phase 1/2 1) 1991: 10 trials (Observational 1, Phase 3 2, Phase 2 4, Phase 1 3) 1992: 10 trials (Observational 4, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1 2) 1993: 8 trials (Observational 2, Not applicable 1, Phase 2 5) 1994: 13 trials (Observational 3, Not applicable 1, Phase 3 3, Phase 1/2 2, Phase 1 4) 1995: 13 trials (Observational 4, Not applicable 1, Phase 3 3, Phase 2 5) 1996: 21 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 6, Phase 2 5, Phase 1/2 1, Phase 1 5) 1997: 32 trials (Observational 2, Not applicable 4, Phase 3 3, Phase 2 12, Phase 1/2 4, Phase 1 7) 1998: 47 trials (Observational 2, Not applicable 2, Phase 3 10, Phase 2/3 1, Phase 2 20, Phase 1 12) 1999: 64 trials (Observational 10, Not applicable 2, Phase 3 13, Phase 2/3 1, Phase 2 23, Phase 1/2 2, Phase 1 13) 2000: 55 trials (Observational 8, Not applicable 7, Phase 3 4, Phase 2/3 1, Phase 2 15, Phase 1/2 4, Phase 1 16) 2001: 71 trials (Observational 9, Not applicable 8, Phase 4 2, Phase 3 6, Phase 2/3 1, Phase 2 27, Phase 1/2 3, Phase 1 15) 2002: 83 trials (Observational 16, Not applicable 12, Phase 4 3, Phase 3 13, Phase 2 26, Phase 1/2 3, Phase 1 10) 2003: 97 trials (Observational 17, Not applicable 5, Phase 4 9, Phase 3 10, Phase 2/3 2, Phase 2 35, Phase 1/2 7, Phase 1 12) 2004: 122 trials (Observational 18, Not applicable 13, Phase 4 8, Phase 3 12, Phase 2 46, Phase 1/2 5, Phase 1 20) 2005: 130 trials (Observational 27, Not applicable 17, Phase 4 9, Phase 3 12, Phase 2 41, Phase 1/2 7, Phase 1 17) 2006: 172 trials (Observational 35, Not applicable 26, Phase 4 8, Phase 3 11, Phase 2/3 4, Phase 2 61, Phase 1/2 6, Phase 1 21) 2007: 182 trials (Observational 37, Not applicable 22, Phase 4 8, Phase 3 18, Phase 2/3 1, Phase 2 54, Phase 1/2 9, Phase 1 33) 2008: 170 trials (Observational 28, Not applicable 22, Phase 4 16, Phase 3 22, Phase 2/3 1, Phase 2 46, Phase 1/2 8, Phase 1 27) 2009: 167 trials (Observational 37, Not applicable 21, Phase 4 11, Phase 3 16, Phase 2/3 3, Phase 2 37, Phase 1/2 15, Phase 1 27) 2010: 177 trials (Observational 31, Not applicable 34, Phase 4 10, Phase 3 11, Phase 2/3 2, Phase 2 49, Phase 1/2 10, Phase 1 30) 2011: 170 trials (Observational 34, Not applicable 26, Phase 4 10, Phase 3 15, Phase 2/3 1, Phase 2 34, Phase 1/2 7, Phase 1 43) 2012: 221 trials (Observational 61, Not applicable 41, Phase 4 22, Phase 3 24, Phase 2/3 2, Phase 2 28, Phase 1/2 21, Phase 1 22) 2013: 194 trials (Observational 57, Not applicable 32, Phase 4 15, Phase 3 17, Phase 2/3 1, Phase 2 36, Phase 1/2 7, Phase 1 29) 2014: 193 trials (Observational 37, Not applicable 48, Phase 4 15, Phase 3 13, Phase 2/3 3, Phase 2 21, Phase 1/2 18, Phase 1 38) 2015: 227 trials (Observational 52, Not applicable 61, Phase 4 9, Phase 3 16, Phase 2 39, Phase 1/2 13, Phase 1 37) 2016: 268 trials (Observational 67, Not applicable 53, Phase 4 18, Phase 3 17, Phase 2/3 7, Phase 2 46, Phase 1/2 21, Phase 1 39) 2017: 262 trials (Observational 62, Not applicable 54, Phase 4 14, Phase 3 15, Phase 2/3 3, Phase 2 37, Phase 1/2 23, Phase 1 54) 2018: 255 trials (Observational 49, Not applicable 56, Phase 4 12, Phase 3 27, Phase 2/3 1, Phase 2 50, Phase 1/2 17, Phase 1 43) 2019: 243 trials (Observational 56, Not applicable 41, Phase 4 14, Phase 3 18, Phase 2/3 4, Phase 2 37, Phase 1/2 21, Phase 1 52) 2020: 257 trials (Observational 68, Not applicable 61, Phase 4 20, Phase 3 18, Phase 2 33, Phase 1/2 19, Phase 1 38) 2021: 345 trials (Observational 92, Not applicable 78, Phase 4 11, Phase 3 23, Phase 2/3 1, Phase 2 47, Phase 1/2 33, Phase 1 60) 2022: 323 trials (Observational 93, Not applicable 82, Phase 4 7, Phase 3 17, Phase 2/3 1, Phase 2 47, Phase 1/2 21, Phase 1 55) 2023: 305 trials (Observational 77, Not applicable 83, Phase 4 9, Phase 3 17, Phase 2/3 6, Phase 2 46, Phase 1/2 28, Phase 1 39) 2024: 323 trials (Observational 93, Not applicable 69, Phase 4 6, Phase 3 15, Phase 2/3 7, Phase 2 50, Phase 1/2 26, Phase 1 57) 2025: 321 trials (Observational 72, Not applicable 93, Phase 4 11, Phase 3 26, Phase 2/3 4, Phase 2 42, Phase 1/2 30, Phase 1 43)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 294
2025 321
2024 323
2023 305
2022 323
2021 345
2020 257
2019 243
2018 255
2017 262

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 350 trials starting in 2026 and about 330 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 621 trials still running at the 2026-10-09 snapshot; registered median of 33 months across 3,411 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Gonadal Disorders trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 973
Phase 1/2 420
Phase 2 1,166
Phase 2/3 63
Phase 3 483
Phase 4 291
Not applicable 1,183
Observational 1,326
Expanded access 9

How many Gonadal Disorders trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 246
Recruiting 813
Enrolling by invitation 24
Active, not recruiting 304
Available 4

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Gonadal Disorders trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 202
Gynecologic Oncology Group 77
AstraZeneca 66
Eli Lilly and Company 40
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 36

Which drugs are being tested for Gonadal Disorders? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
(nab)-paclitaxel 344
PEMBROLIZUMAB 104
Cytoxan 96
TOPOTECAN 94

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
or carboplatin 326
Bevacizumab 1 183
1% Metformin 153
Cisplatin 1 107
Gemcitabine/Gemzar 103

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Gonadal Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Vomiting 1,221 262
Abdominal pain 967 207
Nausea 899 243
Small intestinal obstruction 897 178
Anaemia 887 141

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Gonadal Disorders? (4)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
G protein-coupled receptors involved in GnRH regulation: molecular insights from human disease. Molecular and cellular endocrinology 2011 Yes
A cross-sectional study of metabolic and endocrine complications in beta-thalassemia major. Annals of Saudi medicine 2008 Yes
The existence of a male equivalent of the polycystic ovary syndrome--the present state of the issue. Prague medical report 2006 Yes
The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Human reproduction update 2019 No

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages